Faculty Information - ISHIHARA Hiroki

Published papers

Academic conference presentation

Awards & honors

Education

Rsearch funding number

（Last updated : 2026-07-30 15:47:01）

ISHIHARA Hiroki
Department School of Medicine(Yachiyo Medical Center), School of Medicine

Position Assistant Professor

■ Published papers

1.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2.	Original article	Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3.	Other	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. 2026/05
4.	Other	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. 2026/05
5.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
6.	Other	Prognostic impact of early C-reactive proteindynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. 2026/05
7.	Case report	Requiring caution in the interpretation of donor- derived cell- free DNA levels during cancer treatment in a kidney transplant recipient.: A case report 2026/05
8.	Original article	Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
9.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
10.	Original article	Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations. 2026/03
11.	Case report	Anti-melanoma differentiation-associated Gene 5 antibody-positive interstitial lung disease, Induced by enfortumab vedotin plus pembrolizumab for Advanced urothelial carcinoma. 2026/02/05
12.	Original article	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
13.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
14.	Original article	Treatment profile of first-line immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma in patients with end-stage renal disease on dialysis. 2026/01
15.	Original article	Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
16.	Original article	Impact of polypharmacy on perioperative outcomes of robot‐assisted laparoscopic partial nephrectomy for small renal masses. 2025/09
17.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
18.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
19.	Original article	Genome-wide transcriptome and DNA methylome profiling of acquired cystic disease-associated renal cell carcinoma. 2025/06
20.	Other	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. 2025/05
21.	Other	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. 2025/05
22.	Other	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2025/05
23.	Other	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2025/05
24.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
25.	Original article	Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
26.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
27.	Original article	Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis. 2024/10
28.	Original article	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/09
29.	Original article	Comparison of surgical outcomes of robot‑assisted laparoscopic partial nephrectomy performed by a single experienced surgeon according to two reconstruction methods, including single‑layer and double‑layer renorrhaphy. 2024/07/27
30.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
31.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
32.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
33.	Original article	Editorial comment on prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. 2024/05
34.	Original article	Editorial comment on real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. 2024/05
35.	Original article	Editorial comment to The DDD score outperforms the RENAL score in predicting high-grade renal cell carcinoma. 2024/05
36.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
37.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
38.	Original article	Surgical and functional outcomes of repeat robot-assisted laparoscopic partial nephrectomy compared with repeat open partial nephrectomy. 2024/04
39.	Original article	Comparisons of survival and surgical outcomes between minimally invasive partial nephrectomy and radical nephrectomy in elderly patients with stage 1 renal cell carcinoma. 2024/03
40.	Original article	Predictive factors and oncological outcomes of pathological T3a upstaging in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy. 2024/02
41.	Original article	Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. 2024/01
42.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
43.	Original article	Editorial Comment to Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study. 2023/09
44.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
45.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
46.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
47.	Original article	Editorial Comment on Disease-free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results-Medicare data. 2023/03
48.	Original article	Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
49.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
50.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
51.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
52.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
53.	Original article	Prognostic impact of trial-eligibility criteria in patients with metastatic renal cell carcinoma. 2022/04
54.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
55.	Original article	Association Between Anesthetic Technique and Survival After Radical Nephroureterectomy: A Propensity Score-matching Study. 2022/01
56.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
57.	Original article	Assessment of Feasibility of Robot-assistted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy 2022
58.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
59.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
60.	Original article	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. 2021/12
61.	Original article	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. 2021/11
62.	Original article	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. 2021/10
63.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
64.	Original article	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. 2021/10
65.	Original article	Albumin-to-alkaline phosphatase ratio as a novel prognostic marker of nivolumab monotherapy for previously treated metastatic renal cell carcinoma. 2021/09
66.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
67.	Original article	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. 2021/06
68.	Original article	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. 2021/05
69.	Original article	Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma. 2021/05
70.	Original article	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. 2021/04
71.	Original article	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. 2021/04
72.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
73.	Original article	Predictive role of γ‑glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. 2021/03
74.	Original article	The controlling nutritional status CONUT score in patients with advanced bladder cancer after radical cystectomy. 2021/03
75.	Original article	Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. 2021/02
76.	Original article	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. 2021/01
77.	Original article	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. 2021/01
78.	Original article	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end‐stage renal disease. 2020/11
79.	Original article	Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era? 2020/08
80.	Original article	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. 2020/08
81.	Original article	The de ritis (aspartate transaminase/alanine transaminase) ratio as a prognosticator in patients with end-stage renal disease-associated renal cell carcinoma. 2020/06
82.	Original article	Efficacy of axitinib after nivolumab failure in metastatic renal cell carcinoma. 2020/05
83.	Original article	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. 2020/05
84.	Original article	Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. 2020/05
85.	Original article	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. 2020/05
86.	Original article	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. 2020/04
87.	Review article	Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma. 2019/12
88.	Original article	Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients. 2019/11
89.	Original article	Negative effect of immediate sunitinib interruption on survival in patients with metastatic renal cell carcinoma. 2019/11
90.	Original article	Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma. 2019/11
91.	Original article	Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions. 2019/08
92.	Original article	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. 2019/08
93.	Original article	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers. 2019/08
94.	Original article	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/06
95.	Original article	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. 2019/06
96.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/04
97.	Original article	Prognostic markers for refined stratification of IMDC intermediate-risk metastatic clear cell renal cell carcinoma treated with first-line tyrosine kinase inhibitor therapy. 2019/04
98.	Original article	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019/03
99.	Original article	Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. 2018/12
100.	Original article	Pancreatic cancer cell fraction estimation in a DNA sample. 2018/12
101.	Original article	DNA methylation marker to estimate the breast cancer cell fraction in DNA samples. 2018/11
102.	Original article	Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study. 2018/10
103.	Original article	Immediate progressive disease in patients with metastatic renal cell carcinoma treated with nivolumab: a multi-institution retrospective study. 2018/10
104.	Original article	Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy. 2018/10
105.	Original article	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. 2018/09
106.	Original article	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. 2018/07
107.	Original article	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. 2018/06
108.	Original article	Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. 2018/06
109.	Original article	Prognostic impact of the components of progressive disease on survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2018/06
110.	Original article	Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 2017/12
111.	Original article	Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. 2017/10
112.	Case report	Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Kidney Transplantation: A Multi-Institution Study in Japan Over 30 years. 2017/10
113.	Original article	Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. 2017/09
114.	Original article	Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. 2017/09
115.	Original article	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. 2017/09
116.	Original article	Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy. 2017/08
117.	Case report	Evaluation of first-line sorafenib treatment for metastatic renal cell carcinoma in kidney transplant patients: A single-center experience with four cases. 2017/08
118.	Original article	Evaluation of microvascular inflammation in ABO-incompatible kidney transplantation. 2017/06
119.	Original article	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. 2017/03
120.	Original article	Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. 2017/02
121.	Original article	Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. 2017/02
122.	Original article	Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. 2016/10
123.	Original article	Late recurrence of a malignant hypoglycemia-inducing pelvic solitary fibrous tumor secreting high-molecular-weight insulin-like growth factor-II: A case report with protein analysis. 2016/07
124.	Original article	The magnitude of best tumor shrinkage during second-line targeted therapy affects progressionfree survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/06
125.	Original article	Post-transplant lymphoproliferative disorder in kidney transplant recipients: A single-center experience in Japan. 2016/04
126.	Original article	The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. 2016/03
127.	Original article	Effects of low-dose rituximab therapy in patients with primary cytomegalovirus infection. 2015/12
128.	Original article	Retroperitoneal catecholamine-producing ganglioneuroma with a birth history of monozygotic twins who both suffered from neuroblastoma during their childhoods: A case report with genome analysis. 2015/10
129.	Original article	Anterior urethra sparing cystoprostatectomy for bladder cancer:a 10-year, single center experience. 2015/08
Display 5 items
Display all(129)

■ Academic conference presentation

1.	Association of serum kidney injury molecule-1 (KIM-1)with treatment response and survival in metastaticrenal cell carcinoma. （Poster notice，General） 2026/05/18
2.	Comparison between IO–IO and IO–TKI combination therapies for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice，General） 2026/05/18
3.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （Poster notice，General） 2026/05/18
4.	Prognostic impact of early C-reactive protein dynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. （Poster notice，General） 2026/05/18
5.	Association of Serum Kidney Injury Molecule-1 with Treatment Response and Survival in Metastatic Renal Cell Carcinoma. （Speech，General） 2026/04/25
6.	Initial experience with enfortumab vedotin-pembrolizumab at our hospital. （Speech，General） 2026/04/25
7.	Multicenter study of polypharmacy and perioperative outcomes in robot-assisted laparoscopic radical cystectomy with intracorporeal urinary diversion (ICUD). （Poster notice，General） 2026/04/24
8.	Real-world experience with adjuvant pembrolizumab toxicities in renal cell carcinoma: A single-center experience at Tokyo Women's Medical University. （Speech，General） 2026/04/24
9.	Efficacy of triplet therapy in metastatic castration-sensitive prostate cancer patients at our hospital. （Speech，General） 2026/04/23
10.	Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
11.	Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
12.	Novel peripheral blood immune clustering predicts prognosis and T cell exhaustion in renal cell carcinoma. （Poster notice，General） 2026/04/23
13.	Prognostic impact of early C-reactive protein dynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations. （Speech，General） 2026/04/23
14.	Prognostic significance of B Cell and NK cell infiltration in the tumor immune microenvironment of renal cell carcinoma. （Poster notice，General） 2026/04/23
15.	Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma. （Poster notice，General） 2026/02/28
16.	Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma. （Poster notice，General） 2026/02/28
17.	Early experience of focal therapy using high-intensity focused ultrasound in localized prostate cancer. （Poster notice，General） 2025/10/19
18.	Unmet medical needs in the management of advanced renal cell carcinoma. （Speech） 2025/10/18
19.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
20.	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （Poster notice，General） 2025/04/28
21.	Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors. （Poster notice，General） 2025/04/28
22.	Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. （Poster notice，General） 2025/04/27
23.	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study. （Poster notice，General） 2025/04/26
24.	Clinical outcomes of repeat robot-assisted partial nephrectomy compared to repeat open partial nephrectomy. （Speech，General） 2025/03/23
25.	Prognostic impact of lung immune prognostic index in recurrence after radical surgery for high-risk renal cell carcinoma. （Poster notice，General） 2024/05/05
26.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
27.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
28.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （Poster notice） 2024/04/26
29.	Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3. （Poster notice，General） 2024/04/26
30.	Efficiency of IO-IO combination therapy and IO-TKI combination therapy for renal cell carcinoma with inferior vena cava tumor thrombus. （Poster notice） 2024/04/26
31.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
32.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （Poster notice） 2024/04/26
33.	Primary renal tumor response in patients treated with first-line systemic therapy for advanced renal cell carcinoma. （Poster notice，General） 2024/04/26
34.	Utility of whole-body MRI (DWIBS) in treatment decision-making for M0CRPC: A case series study. （Poster notice，General） 2024/04/26
35.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
36.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
37.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy： Real-world data from Japanese single high-volume center. （Poster notice，General） 2023/04/29
38.	Validation of predictive model for new baseline renal function after radical nephrectomy or robot-assisted partial nephrectomy in Japanese patients. （Poster notice，General） 2023/04/29
39.	Prognostic factors for recurrence after robot-assisted laparoscopic partial nephrectomy: Real-world data from Japanese single high-volume center. （Speech，General） 2023/04/21
40.	Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). A clinicopathological study of 10 Japanese cases. （Poster notice，General） 2023/04/21
41.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
42.	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. （Poster notice，General） 2022/05/16
43.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
44.	Association between ureteral clamping time and acute kidney injury during robot-assisted radical cystectomy. （Poster notice，General） 2022/05/13
45.	C-reactive protein kinetics to predict recurrence after radical surgery for high-risk renal cell carcinoma. （Poster notice，General） 2022/05/13
46.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
47.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
48.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
49.	Genetic and epigenetic alterations in renal cancers developing from end-stage renal disease. （Speech） 2020/12/24
50.	Association between controlling nutritional status（CONUT）score and outcomes after radical cystectomy for advanced bladder cancer. （Speech，General） 2020/12/23
51.	Association between early tumor response and survival in metastatic renal cell carcinoma treated with nivolumab. （Speech，General） 2020/12/23
52.	Comparison of efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. （Speech，General） 2020/12/23
53.	Safety and efficacy of nivolumab for patients with chronic kidney disease. （Speech，General） 2020/12/23
54.	The predictive impact of presurgical sarcopenia on patient survival in patients with renal cell carcinoma with inferior vena cava tumor thrombus. （Speech，General） 2020/12/23
55.	Genetic and epigenetic profiling reveals the proximal tubule origin of renal cancers in end-stage renal disease. （Poster notice，General） 2020/10/01
56.	Comparisons of surgical outcomes between transperitoneal and retroperitoneal　approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: A propensity score-matched comparative analysis. （Speech，General） 2020/07/17
57.	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoingrobot-assisted partial nephrectomy, using enhanced CT. （Speech，General） 2020/07/17
58.	Predictive factors for recurrence after complete metastasectomy in patients with metastaticrenal cell carcinoma in the targeted therapy era. （Speech，General） 2020/07/17
59.	Usefulness of robot-assisted laparoscopic partial nephrectomy using trifecta criteria. （Poster notice，General） 2020/07/17
60.	The significance of microvascular inflammation in antibody-mediated rejection in ABO-incompatible kidney transplantation. （Poster notice，General） 2016/06/13
61.	Sarcopenia and the modified glasgow prognostic score are significant predictors of patient survival in metastatic renal cell carcinoma patients receiving first-line sunitinib treatment. （Poster notice，General） 2016/05/07
Display 5 items
Display all(61)

■ Awards & honors

2016

The American Transplant Congress 2016 American Transplant Congress Best Poster Award (Evaluation of Microvascular Inflammation in ABO-incompatible Kidney Transplantation)

■ Education

1.	2017/04～2021/03	〔Doctoral course〕〔Doctorial Course〕, Tokyo Women's Medical University, Completed,
2.	2005/04～2011/03	Faculty of Medicine, Kanazawa University, Graduated

■ Rsearch funding number

20910821